# Genentech **Source:** https://geo.sig.ai/brands/genentech **Vertical:** Life Sciences & BioTech **Subcategory:** Biopharmaceuticals **Tier:** Leader **Website:** gene.com **Last Updated:** 2026-04-14 ## Summary Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq. ## Company Overview Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub. ## Frequently Asked Questions ### What did Genentech invent? Genentech invented the first recombinant DNA-based human insulin and pioneered the HER2-targeted cancer therapy Herceptin, founding the modern biologics industry. ### Is Genentech independent or part of Roche? Genentech is a wholly owned subsidiary of Roche, acquired in 2009, but retains its own name, campus, and considerable R&D independence. ### What therapeutic areas does Genentech focus on? Genentech focuses on oncology, neuroscience, ophthalmology, and immunology, with blockbuster drugs across cancer immunotherapy, blood cancers, and targeted antibody therapies. ### What are Genentech's biggest drugs by revenue? Genentech's key drugs include Ocrevus (multiple sclerosis), Hemlibra (hemophilia A), Perjeta and Herceptin (HER2+ breast cancer), Avastin (multiple cancers), Tecentriq (PD-L1 checkpoint inhibitor), and Lucentis (age-related macular degeneration) — all blockbusters contributing to Roche's pharmaceutical revenues. ### How does Genentech conduct its R&D? Genentech maintains its own research organization in South San Francisco with approximately 15,000 employees, independently operating research programs despite Roche ownership. This independence has preserved Genentech's entrepreneurial culture and scientific productivity — a key reason Roche allowed it to operate as a named subsidiary rather than integrating it. ### What is Genentech's relationship with Chugai Pharmaceutical? Genentech has a long-standing partnership with Chugai Pharmaceutical (a Roche subsidiary) in Japan, sharing antibody technology access and co-development rights to certain drugs for Japanese markets — part of the broader Roche Group coordination of pharmaceutical assets across regions. ### Where is Genentech headquartered? Genentech is headquartered in South San Francisco, California, at a campus it has occupied since its founding in 1976. The site is widely regarded as the birthplace of the biotechnology industry. ### What did Genentech discover about cancer that changed oncology? Genentech's research on HER2 protein overexpression in breast cancer led to the development of Herceptin (trastuzumab) — the first targeted therapy for a specific molecular subtype of cancer. This proved that targeting cancer-specific proteins could dramatically improve outcomes for a defined patient population, establishing the precision oncology paradigm. ### What is Genentech and what is its relationship to Roche? Genentech is a South San Francisco-based biopharmaceutical company founded in 1976 that pioneered recombinant DNA technology and biotechnology drug development. Roche acquired full ownership of Genentech in 2009 for approximately $47 billion. Genentech operates as a fully integrated subsidiary of Roche, maintaining its own research organization and US commercial operations within the Roche Group. ### What are Genentech's most important approved medicines? Genentech's landmark approved medicines include Herceptin (trastuzumab for HER2+ breast cancer), Avastin (bevacizumab for multiple cancers), Rituxan (rituximab for blood cancers and autoimmune disease), Tecentriq (atezolizumab, PD-L1 checkpoint inhibitor), Ocrevus (ocrelizumab for MS), and Vabysmo (faricimab for retinal diseases)—a portfolio spanning oncology, immunology, and neurology. ### What therapeutic areas does Genentech focus on? Genentech's research focuses on oncology, immunology and inflammatory diseases, and neuroscience. The company applies its foundational antibody engineering capabilities and precision medicine expertise to develop targeted biologics and small molecules that address diseases with significant unmet medical need and clear molecular targets. ### What is Genentech's role in antibody engineering? Genentech pioneered many fundamental antibody engineering technologies and has the world's deepest expertise in therapeutic antibody development. The company's antibody discovery, optimization, and manufacturing capabilities have produced more than 20 FDA-approved medicines and underpin a large portfolio of clinical candidates across its disease focus areas. ### How does Genentech's relationship with Roche benefit its research? Genentech benefits from Roche's global manufacturing scale, commercial infrastructure in international markets, diagnostics capabilities (through Roche Diagnostics), and financial resources of one of the world's largest pharmaceutical companies. Roche's companion diagnostics expertise is particularly valuable given Genentech's precision medicine approach to oncology drug development. ## Tags b2b, global, enterprise, public, healthtech, manufacturing, fortune500 --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*